摘要
目的探讨孟鲁司特钠在儿科哮喘治疗中的临床应用效果。方法将76例哮喘患儿随机均分为2组。对照组给予常规治疗,观察组在对照组的基础上加用孟鲁司特钠。比较2组总体疗效,治疗后4周、8周白天和夜间哮喘发作次数,以及治疗开始后3个月内累积吸入糖皮质激素及速效β2受体激动剂的总量。结果观察组治疗4周、8周后白天、夜间的哮喘发作次数均明显少于对照组,3个月内累积糖皮质激素和速效β2受体激动剂的吸入总量亦少于对照组,且观察组总有效率显著高于对照组。结论孟鲁司特钠在儿科哮喘治疗中的临床应用效果显著,能有效降低急性发作次数,改善临床症状,减少糖皮质激素及β2受体激动剂的使用,且不良反应少,安全可靠,值得临床合理推广。
Objective To explore the clinical effect of montelukast sodium in the treatment of pediatric asthma. Methods 76 cases of pediatric asthma were randomly divided into two groups. The control group （ n = 38） received routine therapy, while the observation group （ n = 38） received montelukast sodium on basis of control group. The total effect, attacking frequency of day and night asthma four and eight weeks after treatment, and accumulated inhalation dose of glucocorticoid and quick- acting β2 receptor stimulating agent with three months were compared. Results The at- tacking frequency of day and night asthma four and eight weeks after treatment, and accumulated inhalation dose of glucocorticoid and quick- acting β2 receptor stimulating agent with three months in observation group were obviously lower than that in control group, and the overall response rate in observation group was still higher than that in control group. Conclusion Montelukast sodium has remarkable effect in pediatric asthma. It can reduce the frequency of acute attacking, improve clinical symptoms, decrease the usage of glucocorticoid and quick - acting β2 receptor stimulating a- gent with few adverse reactions and high security. It＇s worth of reasonable clinical popularization.
出处
《实用临床医药杂志》
CAS
2012年第19期102-104,共3页
Journal of Clinical Medicine in Practice
基金
中国高校医学期刊临床专项资金(11220113)
关键词
孟鲁司特钠
哮喘
儿科
糖皮质激素
Β2受体激动剂
montelukast sodium
asthma
pediatrics
glucocorticoid
β2 receptor stimu- lating agent
